Literature DB >> 9736151

Managed care for congestive heart failure: influence of payer status on process of care, resource utilization, and short-term outcomes.

E F Philbin1, T G DiSalvo.   

Abstract

BACKGROUND: Although health maintenance organizations (HMO) are insuring an increasing number of Americans, there are concerns that cost-reduction strategies may limit access to medical care or jeopardize its quality. This study was conducted to examine the influence of insurance payer status on the process of care and resource utilization among patients hospitalized for congestive heart failure (CHF). METHODS AND
RESULTS: Administrative information on all 1995 New York State hospital discharges assigned ICD-9-CM codes indicative of CHF in the principal diagnosis position were obtained from the Statewide Planning and Research Cooperative System database. The following were compared among patients with HMO, indemnity, Medicaid fee-for-service, and Medicare fee-for-service insurance coverage: demographics, comorbid illness, process of care, length of stay, hospital charges, mortality rate, and CHF readmission rate. A total of 43,157 patients were identified (HMO, 1322; indemnity, 4350; Medicaid, 3878; Medicare, 33 607). Noninvasive procedures were used with similar frequency, whereas greater use of invasive techniques was observed among HMO and indemnity patients. After adjustment for patient characteristics and hospital type and location, HMO care was associated with shorter length of stay and lower hospital charges, the latter partially explained by fewer hospital days. Medicaid patients had the longest length of stay, greatest hospital charges, and highest CHF readmission rate. The adjusted risk of death during the index hospitalization did not vary among insurance groups.
CONCLUSIONS: Though insuring only a small proportion of New Yorkers hospitalized for CHF, managed care plans provide similar access to clinical services while generating fewer charges. Whether these observed differences in short-term outcomes derive from patient mix or quality of care is uncertain and deserves wider prospective study.

Entities:  

Mesh:

Year:  1998        PMID: 9736151     DOI: 10.1016/s0002-8703(98)70234-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

1.  Underuse of invasive procedures among Medicaid patients with acute myocardial infarction.

Authors:  E F Philbin; P A McCullough; T G DiSalvo; G W Dec; P L Jenkins; W D Weaver
Journal:  Am J Public Health       Date:  2001-07       Impact factor: 9.308

2.  Managed care, vertical integration strategies and hospital performance.

Authors:  B B Wang; T T Wan; J Clement; J Begun
Journal:  Health Care Manag Sci       Date:  2001-09

Review 3.  Impact of social factors on risk of readmission or mortality in pneumonia and heart failure: systematic review.

Authors:  Linda Calvillo-King; Danielle Arnold; Kathryn J Eubank; Matthew Lo; Pete Yunyongying; Heather Stieglitz; Ethan A Halm
Journal:  J Gen Intern Med       Date:  2012-10-06       Impact factor: 5.128

Review 4.  Comprehensive multidisciplinary programs for the management of patients with congestive heart failure.

Authors:  E F Philbin
Journal:  J Gen Intern Med       Date:  1999-02       Impact factor: 5.128

5.  Adding socioeconomic data to hospital readmissions calculations may produce more useful results.

Authors:  Elna M Nagasako; Mat Reidhead; Brian Waterman; W Claiborne Dunagan
Journal:  Health Aff (Millwood)       Date:  2014-05       Impact factor: 6.301

6.  Differences in Medicare expenditures during the last 3 years of life.

Authors:  Lisa R Shugarman; Diane E Campbell; Chloe E Bird; Jon Gabel; Thomas A Louis; Joanne Lynn
Journal:  J Gen Intern Med       Date:  2004-02       Impact factor: 5.128

7.  Diagnosis-specific readmission risk prediction using electronic health data: a retrospective cohort study.

Authors:  Courtney Hebert; Chaitanya Shivade; Randi Foraker; Jared Wasserman; Caryn Roth; Hagop Mekhjian; Stanley Lemeshow; Peter Embi
Journal:  BMC Med Inform Decis Mak       Date:  2014-08-04       Impact factor: 2.796

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.